30 results about "Atrophic Vaginitis" patented technology

The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.

The DHEA bioadhesive controlled release gel includes DHEA mixed in a polymeric gel for the purpose of treating atrophic vaginitis, vaginal dryness, dyspareunia, itching, burning, irritation, increase in pH and decreased vaginal flora. The gel adheres to vaginal tissue and protects the DHEA from systemic absorption, which prevents leakage, loss of DHEA, and elevated levels of systemic DHEA. The gel is configured to slowly erode over time so as to deliver a predetermined dose of DHEA to vaginal tissue and thereby promote local intracellular conversion to estrogens, androgens and progesterone so that normal levels of fluid in the vagina is produced. The gel also acts as a moisturizer. An adjustable applicator may also be provided to insure proper placement and dose of the DHEA.

The invention discloses a composition for adjusting vaginal micro ecological balance and / or treating atrophic vaginitis and application thereof. The composition comprises the following raw materials in parts by weight: 500-10,000 parts of lactose monohydrate, 4.5-50 parts of sodium hyaluronate, 4.5-50 parts of PHMB, 0.45-5 parts of L-lactic acid and 113.4-1250 parts of hydroxypropyl methyl cellulose. By adopting the product disclosed by the invention, growth of vaginal lactobacillus is facilitated, a normal physiological environment of the vagina is maintained, the position of dominant bacteria of the lactic acid bacillus is solidified, pH value of the vaginal environment is recovered, vaginal micro ecological balance of bacterial vaginosis is facilitated, and especially to postmenopausal women, the composition has significant effects on improvement of the symptoms such as ovarian function decline, great estrogen reduction, vaginal wall contraction, thinning mucous membrane, reduction of glycogen content in epithelial cells, pH value rise inside vagina, vaginal dryness and the like, and improvement of vagina functions.

The invention discloses a pharmaceutical composition for treating atrophic vaginitis and a preparation method thereof, which aim at solving the problem of treating atrophic vaginitis. The pharmaceutical composition is characterized by being prepared from the following active ingredients: cortex erythrina, smallflower bracketplant herb, tetrapanaxpapyrifer, Tianmu mountain magnolia immature flower, herba taxilli, radix ranunculi ternate, coking malt, scorch-fried medicated leaven, radix ephedrae, spina gleditsiae, peach gum, and cassia twig. Proved by clinical experiments, the drug for treating atrophic vaginitis has the characteristics of good curative effect and higher safety, thus being worth of clinical application and popularization.

The present invention relates generally to a method of down-regulating an inflammatory response in a mammal and to agents useful for same. More particularly, the present invention relates to a method of down-regulating an inflammatory response in the reproductive tract or external genital tissue of a female mammal by contacting the mucosal tissue of the reproductive tract and / or genitalia with lactic acid and to agents useful for same. The method of the present invention is useful, inter alia, in the treatment and / or prophylaxis of conditions characterised by an aberrant, unwanted or otherwise inappropriate inflammatory response including, for example, atrophic vaginitis, irritant vaginitis or infectious vaginitis.

The invention relates to a medicine for treating climacteric syndrome, especially women's senile and atrophic vaginitis and a preparation method thereof. The medicine provided by the invention contains prasterone sulfate sodium. The drug overcomes the defects of the existing drugs, has a good curative effect on the treatment of menopausal syndrome, especially women's senile and atrophic vaginitis, has little toxic and side effects, has no stimulation to the endometrium, and does not cause vaginal bleeding. There is no risk of cancer caused by ordinary hormone therapy.

The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen.

The invention discloses a preparation method of powder for treating atrophic vaginitis, aiming at solving the problem in treating atrophic vaginitis. The preparation method is characterized by comprising the following steps of: (1) carrying out reduced pressure distillation on crude powder of himalayan coralbean bark, ternate buttercup root and ephedra root and extracting volatile oil; (2) carrying out reduced pressure boiling on the volatile oil to obtain a filtrate; (3) boiling Trikeraia hookeri, Magnolia amoena, parasitic loranthus, coked malt, coked medicated leaven, spina gleditsiae, peach gum, cassia twig and the medicinal filtrate obtained in the step (1) so as to obtain a filtrate for later use; (4) combining the filtrates in the steps (2) and (3), carrying out reduced pressure concentration so as to obtain a dry extract, and crushing the dry extract to obtain dry extract powder; (5) ejecting the volatile oil obtained in the step (1) into the dry extract powder obtained in the step (4), uniformly mixing, screening in a sieve of 100 meshes and sub-packaging so as to obtain the powder. Clinical trial shows that the powder has the characteristics of being good in effect on treating atrophic vaginitis and high in security, and is worthy of clinical application and popularization.

The present invention relates to methods for the prevention and treatment of conditions arising from local estrogen deficiency, such as dyspareunia, vulvar atrophy, vaginal atrophy, vaginal dryness, vulvar itching, vaginal itching, vulvar burning, vaginal burning, vulvar dystrophy, atrophic vaginitis or menopausal sexual dysfunction. In some embodiments, the methods include systemic, for example oral, administration of an estrogen, such as conjugated estrogens, and a progestagen, such as MPA, contemporaneously with local administration of an estrogen, for example conjugated estrogens. In some embodiments, the methods include the oral administration of conjugated estrogens and MPA, and the vulvar, vaginal, or vulvar and vaginal administration of conjugated estrogens, for example in a cream.

The present invention discloses pharmaceutical compositions comprising ester derivatives of hyaluronic acid for use as a topical treatment in disorders of the vaginal mucosa characterised by loss of elasticity and hydration, such as vaginal dryness and / or atrophic vaginitis; said compositions can also be used successfully to lubricate the genital mucosa.

The invention discloses a preparation method of powder for treating atrophic vaginitis, aiming at solving the problem in treating atrophic vaginitis. The preparation method is characterized by comprising the following steps of: (1) carrying out reduced pressure distillation on crude powder of himalayan coralbean bark, ternate buttercup root and ephedra root and extracting volatile oil; (2) carrying out reduced pressure boiling on the volatile oil to obtain a filtrate; (3) boiling Trikeraia hookeri, Magnolia amoena, parasitic loranthus, coked malt, coked medicated leaven, spina gleditsiae, peach gum, cassia twig and the medicinal filtrate obtained in the step (1) so as to obtain a filtrate for later use; (4) combining the filtrates in the steps (2) and (3), carrying out reduced pressure concentration so as to obtain a dry extract, and crushing the dry extract to obtain dry extract powder; (5) ejecting the volatile oil obtained in the step (1) into the dry extract powder obtained in the step (4), uniformly mixing, screening in a sieve of 100 meshes and sub-packaging so as to obtain the powder. Clinical trial shows that the powder has the characteristics of being good in effect on treating atrophic vaginitis and high in security, and is worthy of clinical application and popularization.

The invention belongs to the technical field of medicines and particularly relates to heat-clearing and yin-nourishing rice bran oil as well as a preparation method and application thereof. The heat-clearing and yin-nourishing rice bran oil comprises the following components by weight: 40ml-60ml of rice bran oil, 80mg-120mg of vitamin C, 80mg-120mg of sophocarpidine, 130mg-170mg of a radix saposhnikoviae extract, 180mg-220mg of a lily extract and 80mg-120mg of sodium hyaluronate. The heat-clearing and yin-nourishing rice bran oil is helpful for treating atrophic vaginitis and has the characteristics of high efficiency and low relapse rate.